nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2C19—Rosuvastatin—atherosclerosis	0.0628	0.089	CbGbCtD
Tolterodine—CYP2C19—Simvastatin—atherosclerosis	0.0584	0.0827	CbGbCtD
Tolterodine—CYP2C19—Lovastatin—atherosclerosis	0.0572	0.081	CbGbCtD
Tolterodine—CYP2D6—Niacin—atherosclerosis	0.0562	0.0796	CbGbCtD
Tolterodine—CYP2C9—Rosuvastatin—atherosclerosis	0.0523	0.074	CbGbCtD
Tolterodine—CYP2C9—Simvastatin—atherosclerosis	0.0486	0.0688	CbGbCtD
Tolterodine—CYP2C9—Lovastatin—atherosclerosis	0.0475	0.0673	CbGbCtD
Tolterodine—CYP2C9—Pravastatin—atherosclerosis	0.0475	0.0673	CbGbCtD
Tolterodine—CYP2D6—Simvastatin—atherosclerosis	0.0444	0.0629	CbGbCtD
Tolterodine—CYP2D6—Pravastatin—atherosclerosis	0.0435	0.0616	CbGbCtD
Tolterodine—CYP2D6—Lovastatin—atherosclerosis	0.0435	0.0616	CbGbCtD
Tolterodine—CYP3A4—Ezetimibe—atherosclerosis	0.0304	0.043	CbGbCtD
Tolterodine—CYP3A4—Rosuvastatin—atherosclerosis	0.0304	0.043	CbGbCtD
Tolterodine—CYP3A4—Simvastatin—atherosclerosis	0.0282	0.04	CbGbCtD
Tolterodine—CYP3A4—Lovastatin—atherosclerosis	0.0276	0.0391	CbGbCtD
Tolterodine—CYP3A4—Pravastatin—atherosclerosis	0.0276	0.0391	CbGbCtD
Tolterodine—Memory impairment—Rosuvastatin—atherosclerosis	0.00455	0.0244	CcSEcCtD
Tolterodine—Memory impairment—Lovastatin—atherosclerosis	0.00385	0.0207	CcSEcCtD
Tolterodine—Memory impairment—Ezetimibe—atherosclerosis	0.00378	0.0203	CcSEcCtD
Tolterodine—Memory impairment—Simvastatin—atherosclerosis	0.0036	0.0193	CcSEcCtD
Tolterodine—Gastrooesophageal reflux disease—Ezetimibe—atherosclerosis	0.00328	0.0176	CcSEcCtD
Tolterodine—Memory impairment—Pravastatin—atherosclerosis	0.00326	0.0175	CcSEcCtD
Tolterodine—Abnormal vision—Niacin—atherosclerosis	0.00227	0.0121	CcSEcCtD
Tolterodine—Bronchitis—Rosuvastatin—atherosclerosis	0.00215	0.0115	CcSEcCtD
Tolterodine—Dexbrompheniramine—HRH1—atherosclerosis	0.00197	0.253	CrCbGaD
Tolterodine—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00194	0.0104	CcSEcCtD
Tolterodine—Pheniramine—HRH1—atherosclerosis	0.00193	0.247	CrCbGaD
Tolterodine—Sinusitis—Rosuvastatin—atherosclerosis	0.00187	0.01	CcSEcCtD
Tolterodine—Urinary retention—Niacin—atherosclerosis	0.00179	0.00961	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00173	0.00927	CcSEcCtD
Tolterodine—Dry skin—Niacin—atherosclerosis	0.00173	0.00927	CcSEcCtD
Tolterodine—Bronchitis—Simvastatin—atherosclerosis	0.00171	0.00915	CcSEcCtD
Tolterodine—Dry skin—Pravastatin—atherosclerosis	0.0017	0.00912	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00165	0.00884	CcSEcCtD
Tolterodine—Urinary tract infection—Lovastatin—atherosclerosis	0.00164	0.00882	CcSEcCtD
Tolterodine—Sinusitis—Lovastatin—atherosclerosis	0.00159	0.00851	CcSEcCtD
Tolterodine—Bronchitis—Niacin—atherosclerosis	0.00157	0.0084	CcSEcCtD
Tolterodine—Sinusitis—Ezetimibe—atherosclerosis	0.00156	0.00835	CcSEcCtD
Tolterodine—Flatulence—Rosuvastatin—atherosclerosis	0.00154	0.00824	CcSEcCtD
Tolterodine—Dysuria—Pravastatin—atherosclerosis	0.0015	0.00805	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00149	0.008	CcSEcCtD
Tolterodine—Sinusitis—Simvastatin—atherosclerosis	0.00148	0.00796	CcSEcCtD
Tolterodine—Oedema peripheral—Ezetimibe—atherosclerosis	0.00147	0.00787	CcSEcCtD
Tolterodine—Weight increased—Pravastatin—atherosclerosis	0.00146	0.00783	CcSEcCtD
Tolterodine—Angioedema—Rosuvastatin—atherosclerosis	0.00143	0.00764	CcSEcCtD
Tolterodine—Flushing—Lovastatin—atherosclerosis	0.00141	0.00756	CcSEcCtD
Tolterodine—Urinary tract infection—Pravastatin—atherosclerosis	0.00139	0.00746	CcSEcCtD
Tolterodine—Flushing—Ezetimibe—atherosclerosis	0.00138	0.00741	CcSEcCtD
Tolterodine—Sinusitis—Pravastatin—atherosclerosis	0.00134	0.0072	CcSEcCtD
Tolterodine—Arthralgia—Rosuvastatin—atherosclerosis	0.00133	0.00712	CcSEcCtD
Tolterodine—Flushing—Simvastatin—atherosclerosis	0.00132	0.00707	CcSEcCtD
Tolterodine—Flatulence—Lovastatin—atherosclerosis	0.0013	0.00699	CcSEcCtD
Tolterodine—Oedema peripheral—Niacin—atherosclerosis	0.00129	0.00689	CcSEcCtD
Tolterodine—Confusional state—Rosuvastatin—atherosclerosis	0.00128	0.00688	CcSEcCtD
Tolterodine—Flatulence—Ezetimibe—atherosclerosis	0.00128	0.00685	CcSEcCtD
Tolterodine—Infection—Rosuvastatin—atherosclerosis	0.00127	0.00678	CcSEcCtD
Tolterodine—Visual impairment—Niacin—atherosclerosis	0.00126	0.00674	CcSEcCtD
Tolterodine—Bromodiphenhydramine—HRH1—atherosclerosis	0.00126	0.161	CrCbGaD
Tolterodine—Visual impairment—Pravastatin—atherosclerosis	0.00124	0.00664	CcSEcCtD
Tolterodine—Flatulence—Simvastatin—atherosclerosis	0.00122	0.00653	CcSEcCtD
Tolterodine—Flushing—Niacin—atherosclerosis	0.00121	0.00649	CcSEcCtD
Tolterodine—Angioedema—Lovastatin—atherosclerosis	0.00121	0.00648	CcSEcCtD
Tolterodine—Flushing—Pravastatin—atherosclerosis	0.00119	0.00639	CcSEcCtD
Tolterodine—Vertigo—Lovastatin—atherosclerosis	0.00119	0.00637	CcSEcCtD
Tolterodine—Angioedema—Ezetimibe—atherosclerosis	0.00119	0.00635	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00116	0.00622	CcSEcCtD
Tolterodine—Palpitations—Ezetimibe—atherosclerosis	0.00115	0.00614	CcSEcCtD
Tolterodine—Angioedema—Simvastatin—atherosclerosis	0.00113	0.00606	CcSEcCtD
Tolterodine—Arthralgia—Lovastatin—atherosclerosis	0.00113	0.00604	CcSEcCtD
Tolterodine—Chest pain—Lovastatin—atherosclerosis	0.00113	0.00604	CcSEcCtD
Tolterodine—Anxiety—Lovastatin—atherosclerosis	0.00112	0.00601	CcSEcCtD
Tolterodine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00112	0.00601	CcSEcCtD
Tolterodine—Flatulence—Niacin—atherosclerosis	0.00112	0.006	CcSEcCtD
Tolterodine—Vertigo—Simvastatin—atherosclerosis	0.00111	0.00596	CcSEcCtD
Tolterodine—Arthralgia—Ezetimibe—atherosclerosis	0.0011	0.00592	CcSEcCtD
Tolterodine—Chest pain—Ezetimibe—atherosclerosis	0.0011	0.00592	CcSEcCtD
Tolterodine—Flatulence—Pravastatin—atherosclerosis	0.0011	0.00591	CcSEcCtD
Tolterodine—Dry mouth—Lovastatin—atherosclerosis	0.0011	0.0059	CcSEcCtD
Tolterodine—Constipation—Rosuvastatin—atherosclerosis	0.00109	0.00584	CcSEcCtD
Tolterodine—Pain—Rosuvastatin—atherosclerosis	0.00109	0.00584	CcSEcCtD
Tolterodine—Confusional state—Lovastatin—atherosclerosis	0.00109	0.00583	CcSEcCtD
Tolterodine—Dry mouth—Ezetimibe—atherosclerosis	0.00108	0.00579	CcSEcCtD
Tolterodine—Anaphylactic shock—Lovastatin—atherosclerosis	0.00108	0.00579	CcSEcCtD
Tolterodine—Infection—Lovastatin—atherosclerosis	0.00107	0.00575	CcSEcCtD
Tolterodine—Confusional state—Ezetimibe—atherosclerosis	0.00107	0.00572	CcSEcCtD
Tolterodine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00106	0.00567	CcSEcCtD
Tolterodine—Chest pain—Simvastatin—atherosclerosis	0.00105	0.00565	CcSEcCtD
Tolterodine—Arthralgia—Simvastatin—atherosclerosis	0.00105	0.00565	CcSEcCtD
Tolterodine—Infection—Ezetimibe—atherosclerosis	0.00105	0.00564	CcSEcCtD
Tolterodine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00105	0.00563	CcSEcCtD
Tolterodine—Anxiety—Simvastatin—atherosclerosis	0.00105	0.00563	CcSEcCtD
Tolterodine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00104	0.00558	CcSEcCtD
Tolterodine—Angioedema—Niacin—atherosclerosis	0.00104	0.00556	CcSEcCtD
Tolterodine—Angioedema—Pravastatin—atherosclerosis	0.00102	0.00548	CcSEcCtD
Tolterodine—Vertigo—Niacin—atherosclerosis	0.00102	0.00547	CcSEcCtD
Tolterodine—Confusional state—Simvastatin—atherosclerosis	0.00102	0.00546	CcSEcCtD
Tolterodine—Anaphylactic shock—Simvastatin—atherosclerosis	0.00101	0.00541	CcSEcCtD
Tolterodine—Oedema—Simvastatin—atherosclerosis	0.00101	0.00541	CcSEcCtD
Tolterodine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00101	0.0054	CcSEcCtD
Tolterodine—Vertigo—Pravastatin—atherosclerosis	0.001	0.00539	CcSEcCtD
Tolterodine—Palpitations—Niacin—atherosclerosis	0.001	0.00538	CcSEcCtD
Tolterodine—Infection—Simvastatin—atherosclerosis	0.001	0.00538	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000983	0.00527	CcSEcCtD
Tolterodine—Arthralgia—Niacin—atherosclerosis	0.000967	0.00518	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000964	0.00517	CcSEcCtD
Tolterodine—Arthralgia—Pravastatin—atherosclerosis	0.000952	0.0051	CcSEcCtD
Tolterodine—Chest pain—Pravastatin—atherosclerosis	0.000952	0.0051	CcSEcCtD
Tolterodine—Dyspepsia—Lovastatin—atherosclerosis	0.00095	0.00509	CcSEcCtD
Tolterodine—Anxiety—Pravastatin—atherosclerosis	0.000949	0.00509	CcSEcCtD
Tolterodine—Dry mouth—Niacin—atherosclerosis	0.000946	0.00507	CcSEcCtD
Tolterodine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000938	0.00503	CcSEcCtD
Tolterodine—Dyspepsia—Ezetimibe—atherosclerosis	0.000932	0.005	CcSEcCtD
Tolterodine—Fatigue—Lovastatin—atherosclerosis	0.00093	0.00499	CcSEcCtD
Tolterodine—Oedema—Niacin—atherosclerosis	0.000927	0.00497	CcSEcCtD
Tolterodine—Anaphylactic shock—Niacin—atherosclerosis	0.000927	0.00497	CcSEcCtD
Tolterodine—Pain—Lovastatin—atherosclerosis	0.000923	0.00495	CcSEcCtD
Tolterodine—Constipation—Lovastatin—atherosclerosis	0.000923	0.00495	CcSEcCtD
Tolterodine—Confusional state—Pravastatin—atherosclerosis	0.00092	0.00493	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00092	0.00493	CcSEcCtD
Tolterodine—Asthenia—Rosuvastatin—atherosclerosis	0.000914	0.0049	CcSEcCtD
Tolterodine—Oedema—Pravastatin—atherosclerosis	0.000913	0.00489	CcSEcCtD
Tolterodine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000913	0.00489	CcSEcCtD
Tolterodine—Fatigue—Ezetimibe—atherosclerosis	0.000913	0.00489	CcSEcCtD
Tolterodine—Infection—Pravastatin—atherosclerosis	0.000907	0.00486	CcSEcCtD
Tolterodine—Pain—Ezetimibe—atherosclerosis	0.000905	0.00485	CcSEcCtD
Tolterodine—Constipation—Ezetimibe—atherosclerosis	0.000905	0.00485	CcSEcCtD
Tolterodine—Tachycardia—Niacin—atherosclerosis	0.000905	0.00485	CcSEcCtD
Tolterodine—Brompheniramine—HRH1—atherosclerosis	0.000904	0.116	CrCbGaD
Tolterodine—Feeling abnormal—Lovastatin—atherosclerosis	0.000889	0.00477	CcSEcCtD
Tolterodine—Dyspepsia—Simvastatin—atherosclerosis	0.000889	0.00476	CcSEcCtD
Tolterodine—Chlorphenamine—HRH1—atherosclerosis	0.000887	0.114	CrCbGaD
Tolterodine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000882	0.00473	CcSEcCtD
Tolterodine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000872	0.00468	CcSEcCtD
Tolterodine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000871	0.00467	CcSEcCtD
Tolterodine—Fatigue—Simvastatin—atherosclerosis	0.00087	0.00467	CcSEcCtD
Tolterodine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000866	0.00464	CcSEcCtD
Tolterodine—Pain—Simvastatin—atherosclerosis	0.000863	0.00463	CcSEcCtD
Tolterodine—Constipation—Simvastatin—atherosclerosis	0.000863	0.00463	CcSEcCtD
Tolterodine—Abdominal pain—Lovastatin—atherosclerosis	0.000853	0.00457	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000844	0.00453	CcSEcCtD
Tolterodine—Dizziness—Rosuvastatin—atherosclerosis	0.000842	0.00451	CcSEcCtD
Tolterodine—Abdominal pain—Ezetimibe—atherosclerosis	0.000837	0.00449	CcSEcCtD
Tolterodine—Feeling abnormal—Simvastatin—atherosclerosis	0.000832	0.00446	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000831	0.00446	CcSEcCtD
Tolterodine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000825	0.00443	CcSEcCtD
Tolterodine—Somnolence—Niacin—atherosclerosis	0.000824	0.00442	CcSEcCtD
Tolterodine—Dyspepsia—Niacin—atherosclerosis	0.000816	0.00437	CcSEcCtD
Tolterodine—Dyspepsia—Pravastatin—atherosclerosis	0.000803	0.00431	CcSEcCtD
Tolterodine—Abdominal pain—Simvastatin—atherosclerosis	0.000798	0.00428	CcSEcCtD
Tolterodine—Headache—Rosuvastatin—atherosclerosis	0.000798	0.00428	CcSEcCtD
Tolterodine—Hypersensitivity—Lovastatin—atherosclerosis	0.000795	0.00426	CcSEcCtD
Tolterodine—Pain—Niacin—atherosclerosis	0.000793	0.00425	CcSEcCtD
Tolterodine—Fatigue—Pravastatin—atherosclerosis	0.000787	0.00422	CcSEcCtD
Tolterodine—Pain—Pravastatin—atherosclerosis	0.00078	0.00418	CcSEcCtD
Tolterodine—Constipation—Pravastatin—atherosclerosis	0.00078	0.00418	CcSEcCtD
Tolterodine—Hypersensitivity—Ezetimibe—atherosclerosis	0.00078	0.00418	CcSEcCtD
Tolterodine—Asthenia—Lovastatin—atherosclerosis	0.000774	0.00415	CcSEcCtD
Tolterodine—Asthenia—Ezetimibe—atherosclerosis	0.000759	0.00407	CcSEcCtD
Tolterodine—Gastrointestinal pain—Niacin—atherosclerosis	0.000758	0.00406	CcSEcCtD
Tolterodine—Feeling abnormal—Pravastatin—atherosclerosis	0.000752	0.00403	CcSEcCtD
Tolterodine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000746	0.004	CcSEcCtD
Tolterodine—Hypersensitivity—Simvastatin—atherosclerosis	0.000744	0.00399	CcSEcCtD
Tolterodine—Diarrhoea—Lovastatin—atherosclerosis	0.000738	0.00396	CcSEcCtD
Tolterodine—Abdominal pain—Niacin—atherosclerosis	0.000733	0.00393	CcSEcCtD
Tolterodine—Asthenia—Simvastatin—atherosclerosis	0.000724	0.00388	CcSEcCtD
Tolterodine—Diarrhoea—Ezetimibe—atherosclerosis	0.000724	0.00388	CcSEcCtD
Tolterodine—Abdominal pain—Pravastatin—atherosclerosis	0.000721	0.00387	CcSEcCtD
Tolterodine—Dizziness—Lovastatin—atherosclerosis	0.000714	0.00383	CcSEcCtD
Tolterodine—Dizziness—Ezetimibe—atherosclerosis	0.0007	0.00375	CcSEcCtD
Tolterodine—Diarrhoea—Simvastatin—atherosclerosis	0.000691	0.0037	CcSEcCtD
Tolterodine—Hypersensitivity—Niacin—atherosclerosis	0.000683	0.00366	CcSEcCtD
Tolterodine—Headache—Lovastatin—atherosclerosis	0.000676	0.00362	CcSEcCtD
Tolterodine—Hypersensitivity—Pravastatin—atherosclerosis	0.000672	0.0036	CcSEcCtD
Tolterodine—Dizziness—Simvastatin—atherosclerosis	0.000667	0.00358	CcSEcCtD
Tolterodine—Asthenia—Niacin—atherosclerosis	0.000665	0.00357	CcSEcCtD
Tolterodine—Headache—Ezetimibe—atherosclerosis	0.000663	0.00356	CcSEcCtD
Tolterodine—Asthenia—Pravastatin—atherosclerosis	0.000655	0.00351	CcSEcCtD
Tolterodine—Diarrhoea—Niacin—atherosclerosis	0.000634	0.0034	CcSEcCtD
Tolterodine—Headache—Simvastatin—atherosclerosis	0.000632	0.00339	CcSEcCtD
Tolterodine—Diarrhoea—Pravastatin—atherosclerosis	0.000624	0.00335	CcSEcCtD
Tolterodine—Dizziness—Niacin—atherosclerosis	0.000613	0.00329	CcSEcCtD
Tolterodine—Dizziness—Pravastatin—atherosclerosis	0.000603	0.00324	CcSEcCtD
Tolterodine—Headache—Niacin—atherosclerosis	0.000581	0.00311	CcSEcCtD
Tolterodine—Headache—Pravastatin—atherosclerosis	0.000572	0.00307	CcSEcCtD
Tolterodine—Orphenadrine—HRH1—atherosclerosis	0.00057	0.0731	CrCbGaD
Tolterodine—Phenprocoumon—ALB—atherosclerosis	0.000275	0.0354	CrCbGaD
Tolterodine—CHRM1—Signaling Pathways—EDN1—atherosclerosis	1.42e-05	0.000143	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—MAPK3—atherosclerosis	1.42e-05	0.000143	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EDN1—atherosclerosis	1.42e-05	0.000143	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IGF1—atherosclerosis	1.42e-05	0.000143	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—CXCL8—atherosclerosis	1.41e-05	0.000142	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL5—atherosclerosis	1.41e-05	0.000142	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AGT—atherosclerosis	1.41e-05	0.000141	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL5—atherosclerosis	1.41e-05	0.000141	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.41e-05	0.000141	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EDN1—atherosclerosis	1.4e-05	0.000141	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—INS—atherosclerosis	1.4e-05	0.000141	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—HMGCR—atherosclerosis	1.39e-05	0.00014	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL5—atherosclerosis	1.39e-05	0.00014	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOA2—atherosclerosis	1.39e-05	0.00014	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.39e-05	0.00014	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.39e-05	0.00014	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.39e-05	0.00014	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCL2—atherosclerosis	1.38e-05	0.000139	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—LPL—atherosclerosis	1.38e-05	0.000139	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.38e-05	0.000139	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—APOE—atherosclerosis	1.38e-05	0.000139	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—LPL—atherosclerosis	1.38e-05	0.000138	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.37e-05	0.000138	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—CAV1—atherosclerosis	1.37e-05	0.000137	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—APOA1—atherosclerosis	1.36e-05	0.000137	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ABCA1—atherosclerosis	1.36e-05	0.000137	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—LPL—atherosclerosis	1.36e-05	0.000137	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IGF1—atherosclerosis	1.36e-05	0.000136	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SERPINE1—atherosclerosis	1.35e-05	0.000135	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PRKCG—atherosclerosis	1.34e-05	0.000135	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PRKCG—atherosclerosis	1.34e-05	0.000134	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LPA—atherosclerosis	1.33e-05	0.000133	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PRKCG—atherosclerosis	1.32e-05	0.000133	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SPP1—atherosclerosis	1.31e-05	0.000131	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SPP1—atherosclerosis	1.3e-05	0.000131	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	1.3e-05	0.000131	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—CXCL8—atherosclerosis	1.3e-05	0.00013	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SPP1—atherosclerosis	1.29e-05	0.00013	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SERPINE1—atherosclerosis	1.29e-05	0.00013	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NOS3—atherosclerosis	1.29e-05	0.000129	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—BGN—atherosclerosis	1.28e-05	0.000129	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—CXCL8—atherosclerosis	1.28e-05	0.000129	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOA5—atherosclerosis	1.27e-05	0.000128	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.26e-05	0.000126	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.25e-05	0.000126	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CG—atherosclerosis	1.24e-05	0.000125	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ABCA1—atherosclerosis	1.24e-05	0.000125	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NOS3—atherosclerosis	1.23e-05	0.000124	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.22e-05	0.000123	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	1.21e-05	0.000122	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PDGFB—atherosclerosis	1.21e-05	0.000121	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PPARG—atherosclerosis	1.2e-05	0.000121	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PDGFB—atherosclerosis	1.19e-05	0.00012	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.18e-05	0.000119	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AGT—atherosclerosis	1.18e-05	0.000119	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—INS—atherosclerosis	1.18e-05	0.000118	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AGT—atherosclerosis	1.18e-05	0.000118	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—HMOX1—atherosclerosis	1.17e-05	0.000118	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AGT—atherosclerosis	1.17e-05	0.000117	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—LEP—atherosclerosis	1.16e-05	0.000116	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APOE—atherosclerosis	1.16e-05	0.000116	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—LEP—atherosclerosis	1.15e-05	0.000116	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APOE—atherosclerosis	1.15e-05	0.000116	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CAV1—atherosclerosis	1.15e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APOA1—atherosclerosis	1.14e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CAV1—atherosclerosis	1.14e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APOE—atherosclerosis	1.14e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—LEP—atherosclerosis	1.14e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CXCL8—atherosclerosis	1.14e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APOA1—atherosclerosis	1.14e-05	0.000115	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CAV1—atherosclerosis	1.13e-05	0.000114	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APOA1—atherosclerosis	1.13e-05	0.000113	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOB—atherosclerosis	1.12e-05	0.000113	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ESR1—atherosclerosis	1.1e-05	0.000111	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—AKT1—atherosclerosis	1.1e-05	0.000111	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ESR1—atherosclerosis	1.1e-05	0.000111	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CXCL8—atherosclerosis	1.09e-05	0.00011	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—F2—atherosclerosis	1.09e-05	0.00011	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ESR1—atherosclerosis	1.09e-05	0.00011	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTM1—atherosclerosis	1.09e-05	0.00011	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—F2—atherosclerosis	1.09e-05	0.000109	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL6—atherosclerosis	1.08e-05	0.000109	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ALB—atherosclerosis	1.08e-05	0.000109	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—F2—atherosclerosis	1.08e-05	0.000108	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.08e-05	0.000108	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—LPL—atherosclerosis	1.07e-05	0.000108	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.07e-05	0.000107	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.06e-05	0.000107	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—AKT1—atherosclerosis	1.05e-05	0.000106	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LIPC—atherosclerosis	1.05e-05	0.000106	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOC3—atherosclerosis	1.05e-05	0.000105	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	1.04e-05	0.000105	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GPX1—atherosclerosis	1.04e-05	0.000105	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LDLR—atherosclerosis	1.04e-05	0.000105	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	1.04e-05	0.000105	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—atherosclerosis	1.04e-05	0.000104	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—NOS3—atherosclerosis	1.03e-05	0.000104	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—atherosclerosis	1.03e-05	0.000104	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	1.03e-05	0.000104	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOB—atherosclerosis	1.03e-05	0.000104	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOB—atherosclerosis	1.02e-05	0.000103	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NFKB1—atherosclerosis	1.02e-05	0.000103	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CETP—atherosclerosis	1.02e-05	0.000102	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CD36—atherosclerosis	1.02e-05	0.000102	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK8—atherosclerosis	1e-05	0.000101	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—atherosclerosis	1e-05	0.000101	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—AKT1—atherosclerosis	1e-05	0.000101	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	1e-05	0.000101	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	9.97e-06	0.0001	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—atherosclerosis	9.93e-06	9.99e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—INS—atherosclerosis	9.88e-06	9.93e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—atherosclerosis	9.87e-06	9.93e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	9.87e-06	9.92e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—INS—atherosclerosis	9.85e-06	9.9e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—LPL—atherosclerosis	9.84e-06	9.89e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NFKB1—atherosclerosis	9.77e-06	9.82e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—INS—atherosclerosis	9.75e-06	9.81e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—LPL—atherosclerosis	9.75e-06	9.8e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SCARB1—atherosclerosis	9.74e-06	9.79e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL2—atherosclerosis	9.72e-06	9.77e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL2—atherosclerosis	9.69e-06	9.74e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MTHFR—atherosclerosis	9.63e-06	9.68e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK8—atherosclerosis	9.6e-06	9.65e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL2—atherosclerosis	9.6e-06	9.65e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GPX1—atherosclerosis	9.6e-06	9.65e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—atherosclerosis	9.58e-06	9.63e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1—atherosclerosis	9.56e-06	9.61e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1—atherosclerosis	9.53e-06	9.58e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GPX1—atherosclerosis	9.51e-06	9.56e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—atherosclerosis	9.45e-06	9.5e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARA—atherosclerosis	9.45e-06	9.5e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1—atherosclerosis	9.43e-06	9.49e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CD36—atherosclerosis	9.35e-06	9.4e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CD36—atherosclerosis	9.26e-06	9.31e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—atherosclerosis	9.26e-06	9.31e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMGCR—atherosclerosis	9.19e-06	9.24e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—atherosclerosis	9.17e-06	9.22e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AGT—atherosclerosis	9.15e-06	9.2e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	9.08e-06	9.12e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	9.05e-06	9.1e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOE—atherosclerosis	8.96e-06	9.01e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	8.96e-06	9.01e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CAV1—atherosclerosis	8.88e-06	8.93e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	8.87e-06	8.91e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOA1—atherosclerosis	8.86e-06	8.91e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MTHFR—atherosclerosis	8.86e-06	8.9e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MTHFR—atherosclerosis	8.78e-06	8.83e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—atherosclerosis	8.78e-06	8.83e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	8.76e-06	8.81e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARA—atherosclerosis	8.69e-06	8.73e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	8.67e-06	8.71e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOS3—atherosclerosis	8.64e-06	8.68e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARA—atherosclerosis	8.61e-06	8.66e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOS3—atherosclerosis	8.55e-06	8.6e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	8.5e-06	8.54e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AGT—atherosclerosis	8.41e-06	8.46e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	8.39e-06	8.43e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AGT—atherosclerosis	8.34e-06	8.39e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOE—atherosclerosis	8.24e-06	8.29e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCA1—atherosclerosis	8.2e-06	8.24e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOE—atherosclerosis	8.17e-06	8.22e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CAV1—atherosclerosis	8.17e-06	8.21e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOA1—atherosclerosis	8.15e-06	8.19e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	8.14e-06	8.18e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CAV1—atherosclerosis	8.1e-06	8.14e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	8.09e-06	8.13e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOA1—atherosclerosis	8.08e-06	8.12e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARG—atherosclerosis	7.81e-06	7.85e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	7.69e-06	7.73e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	7.66e-06	7.7e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—INS—atherosclerosis	7.66e-06	7.7e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	7.59e-06	7.63e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	7.44e-06	7.48e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	7.43e-06	7.47e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	7.4e-06	7.44e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	7.38e-06	7.42e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	7.33e-06	7.37e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	7.31e-06	7.35e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	7.29e-06	7.32e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	7.22e-06	7.25e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARG—atherosclerosis	7.18e-06	7.22e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARG—atherosclerosis	7.12e-06	7.16e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—INS—atherosclerosis	7.04e-06	7.08e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMOX1—atherosclerosis	7.03e-06	7.07e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—atherosclerosis	7.02e-06	7.06e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—INS—atherosclerosis	6.98e-06	7.02e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	6.95e-06	6.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	6.93e-06	6.97e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	6.88e-06	6.92e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	6.86e-06	6.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	6.86e-06	6.89e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	6.79e-06	6.83e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	6.76e-06	6.8e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	6.74e-06	6.78e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	6.74e-06	6.78e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOB—atherosclerosis	6.73e-06	6.77e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	6.72e-06	6.76e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NOS3—atherosclerosis	6.72e-06	6.75e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	6.67e-06	6.71e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	6.66e-06	6.69e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—atherosclerosis	6.55e-06	6.59e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—atherosclerosis	6.46e-06	6.49e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LPL—atherosclerosis	6.43e-06	6.47e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—atherosclerosis	6.4e-06	6.44e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—atherosclerosis	6.4e-06	6.44e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GPX1—atherosclerosis	6.27e-06	6.31e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	6.24e-06	6.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	6.22e-06	6.26e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	6.18e-06	6.21e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NOS3—atherosclerosis	6.18e-06	6.21e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	6.16e-06	6.2e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	6.16e-06	6.19e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—atherosclerosis	6.14e-06	6.17e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—atherosclerosis	6.13e-06	6.17e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NOS3—atherosclerosis	6.12e-06	6.16e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CD36—atherosclerosis	6.11e-06	6.14e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	6.1e-06	6.13e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	5.91e-06	5.94e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	5.91e-06	5.94e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	5.89e-06	5.92e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	5.83e-06	5.86e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTHFR—atherosclerosis	5.79e-06	5.82e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	5.73e-06	5.76e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	5.71e-06	5.74e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARA—atherosclerosis	5.68e-06	5.71e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	5.66e-06	5.69e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	5.66e-06	5.69e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—atherosclerosis	5.65e-06	5.68e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—atherosclerosis	5.6e-06	5.63e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AGT—atherosclerosis	5.5e-06	5.53e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOE—atherosclerosis	5.39e-06	5.42e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CAV1—atherosclerosis	5.34e-06	5.37e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOA1—atherosclerosis	5.33e-06	5.36e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	4.86e-06	4.89e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—atherosclerosis	4.75e-06	4.77e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARG—atherosclerosis	4.7e-06	4.72e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—INS—atherosclerosis	4.6e-06	4.63e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—atherosclerosis	4.32e-06	4.34e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—atherosclerosis	4.3e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—atherosclerosis	4.26e-06	4.29e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—atherosclerosis	4.22e-06	4.24e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NOS3—atherosclerosis	4.04e-06	4.06e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	3.98e-06	4e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	3.97e-06	3.99e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	3.93e-06	3.95e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.69e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—atherosclerosis	3.09e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—atherosclerosis	2.84e-06	2.85e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—atherosclerosis	2.81e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—atherosclerosis	1.86e-06	1.87e-05	CbGpPWpGaD
